Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod

Alessandro D'Ambrosio; Rocco Capuano; Settimio Rossi; Alvino Bisecco; Michele Lanza; Carlo Gesualdo; Letizia Leocani; Mariaemma Rodegher; Massimo Filippi; Clara Marino; Davide Maimone; Gioacchino Tedeschi; Francesca Simonelli; Antonio Gallo

doi:10.1007/s10072-020-04802-x

Related publications

Letter2012

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients

Angelo Ghezzi, Maria A. Rocca, Damiano Baroncini, Pietro Annovazzi, Mauro Zaffaroni, G. Minonzio, Gıancarlo Comı, Massimo Filippi

Article2018

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

Laura Ferrè, Ferdinando Clarelli, Giacomo Sferruzza, Maria A. Rocca, Elisabetta Mascia, Marta Radaelli, Francesca Sangalli, Gloria Dalla Costa, Lucia Moiola, M Aboulwafa, Filippo Martinelli Boneschi, Gıancarlo Comı, Massimo Filippi, Vittorio Martinelli, Federica Esposito

Article2020

Two-year regional grey and white matter volume changes with natalizumab and fingolimod

Paolo Preziosa, Maria A. Rocca, Elisabetta Pagani, Loredana Storelli, Mariaemma Rodegher, Lucia Moiola, Massimo Filippi

Preprint2020

COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis

Amir‐Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana Beretich, James Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara HW Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi

Article2020

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana Beretich, James Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi